Lyra Therapeutics, Inc.
LYRA
$4.19
$0.184.49%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -86.34% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -86.34% | 0.00% | |||
| Cost of Revenue | -20.80% | 4.80% | |||
| Gross Profit | 18.37% | -4.99% | |||
| SG&A Expenses | -36.13% | 7.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.04% | 5.80% | |||
| Operating Income | 25.75% | -5.93% | |||
| Income Before Tax | 19.56% | 12.97% | |||
| Income Tax Expenses | 50.00% | -50.00% | |||
| Earnings from Continuing Operations | 19.54% | 12.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 19.54% | 12.99% | |||
| EBIT | 25.75% | -5.93% | |||
| EBITDA | 25.86% | -6.04% | |||
| EPS Basic | 38.62% | 15.15% | |||
| Normalized Basic EPS | 42.89% | -2.10% | |||
| EPS Diluted | 38.62% | 15.15% | |||
| Normalized Diluted EPS | 42.89% | -2.10% | |||
| Average Basic Shares Outstanding | 31.08% | 2.54% | |||
| Average Diluted Shares Outstanding | 31.08% | 2.54% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||